MANY PATIENTS IN THE FIRST TRIAL WERE >75 YEARS OLD OR HAD RENAL IMPAIRMENT.1,3
>75 years of age
Median age of 73 years (range 40-92)
Moderate to severe renal impairment
(CrCl ≤50 mL/min, excluding patients on dialysis)
Demographics and disease-related baseline characteristics of patients were balanced across study arms.1-3
References: 1. REVLIMID [package insert]. Summit, NJ: Celgene Corp. 2. Data on file. Celgene Corp; 2018. 3. Benboubker L, Dimopoulos MA, Dispenzieri A, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014;371(10):906-917.